
Eye-drug maker Harrow's HROW shares rise 2.09% to $31.32
Brokerage H.C. Wainwright starts coverage on HROW with "buy" rating; sets PT at $57
Brokerage sees rapid growth driven by co's branded products for eye diseases
Expects HROW to continue to make meaningful and sensible buys
Says its eye drop Vevye compares well to other dry eye treatments
Says that other eye products that are used during surgical procedures such as Iheezo and Triesence also serve as growth drivers
The PT is a 84.5% upside to the stock's last close
Stock rose ~232% in the last 12 months